Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
09 Janeiro 2024 - 9:30AM
Emergent BioSolutions (NYSE: EBS), a global company providing
solutions that address public health threats and brings lifesaving,
life-extending products to market, today announced that Haywood
Miller, Interim Chief Executive Officer and Rich Lindahl, Chief
Financial Officer, will present at the 42nd Annual J.P. Morgan
Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m.
PT.
The audio link for Emergent's session may be accessed here, and
will be live for up to 30 days.
The company’s slides will be made available at the time of the
presentation on the Investors section of the Emergent website.
About Emergent BioSolutionsAt Emergent, our
mission is to protect and enhance life. For 25 years, we’ve been at
work defending people from things we hope will never happen—so we
are prepared just in case they ever do. We provide solutions for
complex and urgent public health threats through a portfolio of
vaccines and therapeutics that we develop and manufacture for
governments and consumers. We also offer a range of integrated
contract development and manufacturing services for pharmaceutical
and biotechnology customers. To learn more about how we plan to
protect or enhance 1 billion lives by 2030, visit our website and
follow us on LinkedIn, X (formerly Twitter),
and Instagram.
Safe Harbor StatementThis communication, and
the presentation to which it relates, include forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements, other than statements of
historical fact, are forward-looking statements. We generally
identify forward-looking statements by using words like
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,”
“possible,” “potential,” “predict,” “project,” “should,” “target,”
“will,” “would,” and similar expressions or variations thereof, or
the negative thereof, but these terms are not the exclusive means
of identifying such statements. Forward-looking statements are
based on our current intentions, beliefs and expectations regarding
future events based on information that is currently available. We
cannot guarantee that any forward-looking statement will be
accurate. Readers should realize that if underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize,
actual results could differ materially from our expectations.
Readers are, therefore, cautioned not to place undue reliance on
any forward-looking statements. Any forward-looking statement
speaks only as of the date of this communication and, except as
required by law, we do not undertake any obligation to update any
forward-looking statement to reflect new information, events or
circumstances.
There are a number of important factors that could cause our
actual results to differ materially from those indicated by any
forward-looking statements. Readers should consider this cautionary
statement, as well as the risk factors and other disclosures
included in our periodic reports filed with the Securities and
Exchange Commission, when evaluating our forward-looking
statements.
Investor Contact:Richard S. LindahlExecutive
Vice President, CFOlindahlr@ebsi.com
Media Contact:Assal HellmerVice President,
Communicationsmediarelations@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Emergent Biosolutions (NYSE:EBS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024